Another state has signed on to a “Netflix” style payment model for hepatitis C drugs.

Washington state now joins Louisiana in paying a flat rate for “cheap” access to the drugs. It has agreed to give AbbVie some $321 million to treat about 30,000 patients with its glecaprevir/pibrentasvir combo pill (Mavyret) over four years.